This week, Redoxis CEO Malin Hultqvist Davidsson is attending BIOJapan to meet international partners and explore new collaborations within drug discovery and development.
At Redoxis, we specialize in preclinical services for inflammation and autoimmune diseases, offering deep scientific expertise and a broad portfolio of in vivo and in vitro models — supporting characterization and efficacy evaluation across modalities, from small molecules to cell and gene therapies.
Our mission is to combine scientific knowledge, ethical responsibility, and quality-driven processes to help our partners advance novel therapies toward clinical success.
If you are attending BIOJapan, we welcome you to connect through the partnering platform or reach out directly to schedule a meeting.